Effectiveness of nonsteroidal anti-inflammatory drugs in prevention of post-ERCP pancreatitis: A meta-analysis

Table 1 Characteristics of the included articles n (%)

Ref.	Year	Country	Setting	Number of patients	NSAID dose and duration	PEP in NSAID group	PEP in placebo group
Murray et al[18]	2003	Scotland	Single center	220	Suppository, 100 mg after ERCP	7 (6.4)	17 (15.5)
Cheon et al[17]	2007	United States	Single center	207	Oral, 50 mg before and after ERCP	17 (16.2)	17 (16.7)
Sotoudehmanesh et al[9]	2007	Iran	Single center	480	Suppository, 100 mg before ERCP	7 (2.8)	15 (6.1)
Montaño Loza et al[19]	2007	Mexico	Single center	150	Suppository, 100 mg before ERCP	4 (5.3)	-
Khoshbaten et al[16]	2008	Iran	Single center	100	Suppository, 100 mg after ERCP	2 (4.0)	13 (26.0)
Senol et al[15]	2009	Turkey	Single center	80	Infusion, 75 mg after ERCP	3 (7.5)	7 (17.5)
Elmunzer et al[14]	2012	United States	Multi-center	602	Suppository, 50 mg after ERCP	27 (9.1)	52 (25.1)
Otsuka et al[5]	2012	Japan	Single center	104	Suppository, 50 mg before ERCP	2 (3.9)	10 (18.9)

ERCP: Endoscopic retrograde cholangiopancreatography; NSAID: Nonsteroidal anti-inflammatory drug; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.